Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors
A Prospective Study of Plasma Cell-free DNA Fragmentomics for Early Detection of Pancreatic Neuroendocrine Tumors and Differential Diagnosis of Solid Pancreatic Tumors
Fudan University
1,000 participants
Feb 27, 2023
OBSERVATIONAL
Conditions
Summary
This prospective study aims to evaluate the sensitivity and specificity of an integrated model using fragmentomic profiles of plasma cell-free DNA for early detection of pancreatic neuroendocrine tumors and differential diagnosis of solid pancreatic tumors.
Eligibility
Inclusion Criteria6
- Age 18 and above, regardless of gender;
- Histopathological diagnosis with non-functional pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor;
- Not receiving any anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;
- No obvious surgical contraindications;
- Able to comply with research plans, follow-up plans, and other protocol requirements;
- Voluntary participation and signed informed consent.
Exclusion Criteria9
- Pathological diagnosis was not pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor;
- Currently diagnosed with other types of tumors or any cancer history;
- Diagnosed with familial syndromes;
- Receiving anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;
- Ongoing fever or recipient of anti-inflammation therapy within 14 days prior to study blood draw;
- Recipient of blood transfusion within 30 days prior to study blood draw;
- Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant;
- Poor health condition and not suitable for blood draw;
- Any other disease/condition deemed not suitable for study enrollment by researcher.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Blood collection for fragmentomic profiles of plasma cell-free DNA. The sub-center shall use the same blood collection consumables (EDTA anticoagulant vacutainer tubes) and blood collection volume (10ml) as the main center; plasma separation shall be completed within 2 hours after blood collection, and all operations shall comply with the study's unified SOP.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05847855